The Survival Impact of Palliative Chemotherapy Dose Modifications on Metastatic Colon Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Jul 5

PMID 35787795

Authors

Mohd Naqib Zainal Abidin

Marhanis Salihah Omar

Farida Islahudin

Noraida Mohamed Shah

Affiliations

Soon will be listed here.

Abstract

Background: An uninterrupted dose of oxaliplatin-based cytotoxic therapy is an essential component in the standard treatment regimen of metastatic colon cancer (mCC). Data on the impacts of dose intensity reduction on the palliative treatment for patients with mCC remain scarce. Hence, this study aimed to investigate the impact of palliative chemotherapy dose modifications (DM) on the survival of patients with mCC.

Methods: Patients with stage IV colon cancer who received first-line palliative FOLFOX regimen chemotherapy between 2014 until 2018 in the Oncology Department of the National Cancer Institute were conveniently sampled retrospectively to analyse the treatment efficacy. The cumulative dose and duration of chemotherapy received by the patients were summarised as relative dose intensity (RDI) and stratified as High RDI (RDI ≥ 70%) or Low RDI (RDI < 70%). Progression-free survival (PFS) and 2-year overall survival (OS) between the two groups were analysed using Kaplan-Meier survival analysis and Cox proportional hazards models.

Results: Out of the 414 patients identified, 95 patients with mCC were eligible and included in the final analysis. About half of the patients (n = 47) completed the 12-cycle chemotherapy regimen and one patient received the complete (100%) RDI. The overall median RDI was 68.7%. The Low RDI group (n = 49) had a 1.5 times higher mortality risk than the High RDI group [OS, Hazard Ratio (HR) = 1.5, 95% Cl: 1.19-1.82] with a significant median OS difference (9.1 vs. 16.0 months, p < 0.01). Furthermore, patients with lower dose intensity showed double the risk of disease progression (PFS, HR = 2.0, 95% CI: 1.23-3.13) with a significant difference of 4.5 months of median PFS (p < 0.01). Gender and RDI were the independent prognostic factors of both OS and PFS.

Conclusion: Reduction in the dose intensity of palliative chemotherapy may adversely affect both disease progression and overall survival among mCC patients.

Citing Articles

Differential Effects of a Telemonitoring Platform in the Development of Chemotherapy-Associated Toxicity: A Randomized Trial Protocol.

Martinez F, Taramasco C, Espinoza M, Acevedo J, Goic C, Nervi B Diagnostics (Basel). 2024; 14(6).

PMID: 38535039 PMC: 10968981. DOI: 10.3390/diagnostics14060619.

References

Halabi S, Owzar K . The importance of identifying and validating prognostic factors in oncology. Semin Oncol. 2010; 37(2):e9-18. PMC: 2929829. DOI: 10.1053/j.seminoncol.2010.04.001. View

Paulson E, Wirtalla C, Armstrong K, Mahmoud N . Gender influences treatment and survival in colorectal cancer surgery. Dis Colon Rectum. 2009; 52(12):1982-91. DOI: 10.1007/DCR.0b013e3181beb42a. View

Munker S, Gerken M, Fest P, Ott C, Schnoy E, Fichtner-Feigl S . Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects. BMC Cancer. 2018; 18(1):455. PMC: 5913883. DOI: 10.1186/s12885-018-4380-z. View

Smyth J, Hardcastle J, Denton G, Alderson D, Grace R, Mansi J . Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Ann Oncol. 1995; 6(9):948-9. DOI: 10.1093/oxfordjournals.annonc.a059365. View

Hryniuk W . The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol. 1988; :121-41. View

Raphael M, Biagi J, Kong W, Mates M, Booth C, Mackillop W . The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2016; 160(1):17-28. DOI: 10.1007/s10549-016-3960-3. View

Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2003; 22(2):229-37. DOI: 10.1200/JCO.2004.05.113. View

Hassan M, Ismail I, Mohd Suan M, Ahmad F, Wan Khazim W, Othman Z . Incidence and mortality rates of colorectal cancer in Malaysia. Epidemiol Health. 2016; 38:e2016007. PMC: 5081307. DOI: 10.4178/epih.e2016007. View

Wan Puteh S, Saad N, Aljunid S, Abdul Manaf M, Sulong S, Sagap I . Quality of life in Malaysian colorectal cancer patients. Asia Pac Psychiatry. 2013; 5 Suppl 1:110-7. DOI: 10.1111/appy.12055. View

10.

Gerard A, Buyse M, Pector J, Bleiberg H, Arnaud J, Willems G . Hepatic artery ligation with and without portal infusion of 5-FU. A randomized study in patients with unresectable liver metastases from colorectal carcinoma. The E.O.R.T.C. Gastrointestinal Cancer Cooperative Group (G.I. Group). Eur J Surg Oncol. 1991; 17(3):289-94. View

11.

Seymour M, Stenning S, Cassidy J . Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council. Clin Oncol (R Coll Radiol). 1997; 9(4):248-51. DOI: 10.1016/s0936-6555(97)80010-6. View

12.

Van Cutsem E, Cervantes A, Nordlinger B, Arnold D . Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3:iii1-9. DOI: 10.1093/annonc/mdu260. View

13.

Redmond K . Assessing patients' needs and preferences in the management of advanced colorectal cancer. Br J Cancer. 1998; 77 Suppl 2:5-7. PMC: 2149720. DOI: 10.1038/bjc.1998.419. View

14.

Park D, Baek S, Kwak J, Kim J, Kim S . Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer. Ann Surg Treat Res. 2018; 94(4):196-202. PMC: 5880977. DOI: 10.4174/astr.2018.94.4.196. View

15.

Frasci G . Treatment of breast cancer with chemotherapy in combination with filgrastim: approaches to improving therapeutic outcome. Drugs. 2002; 62 Suppl 1:17-31. DOI: 10.2165/00003495-200262001-00002. View

16.

Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Gilles V . Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol. 2001; 11(11):1477-83. DOI: 10.1023/a:1026520812351. View

17.

Hanna T, King W, Thibodeau S, Jalink M, Paulin G, Harvey-Jones E . Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020; 371:m4087. PMC: 7610021. DOI: 10.1136/bmj.m4087. View

18.

. Palliative chemotherapy for advanced or metastatic colorectal cancer. Colorectal Meta-analysis Collaboration. Cochrane Database Syst Rev. 2000; (2):CD001545. PMC: 7025779. DOI: 10.1002/14651858.CD001545. View

19.

Murakawa Y, Sakayori M, Otsuka K . Impact of palliative chemotherapy and best supportive care on overall survival and length of hospitalization in patients with incurable Cancer: a 4-year single institution experience in Japan. BMC Palliat Care. 2019; 18(1):45. PMC: 6547558. DOI: 10.1186/s12904-019-0428-3. View

20.

Zhou M, Thompson T, Lin H, Chen V, Karlitz J, Fontham E . Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients. Clin Colorectal Cancer. 2021; 21(2):e62-e75. PMC: 8971135. DOI: 10.1016/j.clcc.2021.09.008. View